Financial Performance - The company's operating revenue for the first half of 2020 was ¥878,804,020.34, representing a decrease of 19.90% compared to ¥1,097,111,502.99 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥99,087,263.48, down 27.65% from ¥136,951,416.48 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥85,470,789.38, a decrease of 10.94% compared to ¥95,973,067.56 in the same period last year[19]. - The net cash flow from operating activities was -¥78,604,171.18, a decline of 133.55% from ¥234,281,882.49 in the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,522,860,662.53, down 6.52% from ¥1,628,991,717.25 at the end of the previous year[19]. - Total assets decreased by 9.78%, amounting to ¥2,220,666,018.83 compared to ¥2,461,373,036.61 at the end of the previous year[19]. - Basic earnings per share decreased by 25.51% to CNY 0.73 compared to the same period last year[20]. - Diluted earnings per share also decreased by 25.51% to CNY 0.73 compared to the same period last year[20]. - The weighted average return on equity fell to 6.03%, down 2.81 percentage points from the previous year[20]. - In the first half of 2020, the company's revenue decreased by 19.90% year-on-year, and net profit decreased by 27.65%, showing a gradual reduction in the decline compared to the first quarter where revenue dropped by 36.17% and net profit by 48.75%[52]. Market Presence and Strategy - The company operates under a multi-channel sales model, including direct sales, e-commerce, and ODM for both domestic and international markets[29]. - The company has established a strong presence in the shared massage service market, with operations in 32 provinces and 2,164 cities[34]. - The company focuses on a light-asset model by transferring most self-operated massage chairs to quality operators, enhancing operational efficiency[35]. - The company’s main products include various massage chairs and small massage devices, catering to diverse consumer needs[25][27]. - The company operates under multiple brands, including "Rongtai" and "Momo Da," targeting different consumer segments to effectively capture market share[45]. - The company has established a multi-channel marketing strategy, including e-commerce platforms and physical retail locations, to enhance sales growth[47]. - The company signed a cooperation agreement with Walt Disney (China) Co., Ltd., launching themed exhibitions to enhance brand image and attract younger consumers[54]. - The company achieved a global cumulative sales volume of over 1,700,000 massage chairs by the end of the reporting period, with significant online sales performance during major shopping events[53]. Research and Development - The company emphasizes technological innovation in product development, including AI interaction and health data monitoring, to enhance user experience[44]. - The company increased R&D investment, with 14 ongoing projects and 21 invention patents applied for, enhancing product competitiveness through technological innovation[58]. - Research and development expenses decreased by 19.74% to ¥44,157,071.81 from ¥55,019,384.82 year-on-year[65]. Financial Management - The company implemented a robust accounts receivable and sales credit management mechanism, ensuring good cash flow management and sustainable growth[50]. - The company introduced advanced ERP/MES systems for smart production, optimizing production processes and improving operational efficiency[52]. - The company reported a total profit of ¥104.09 million, down from ¥152.56 million, reflecting a decline of approximately 32%[147]. - The company reported cash inflow from investment activities of CNY 136,869,910.91, a significant improvement from a cash outflow of CNY 161,027,989.05 in the previous year[154]. Risks and Challenges - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is attributed to raw materials, which could impact net profit growth[85]. - The company has a significant reliance on a major client, BODY FRIEND, which poses a risk if sales growth from this client does not continue[86]. - The company is exposed to foreign exchange risks due to its export business primarily settled in USD, which could affect operating performance[88]. - The COVID-19 pandemic has caused significant disruptions to the company's production and sales, leading to potential volatility in performance[91]. Shareholder and Corporate Governance - The company held its first extraordinary general meeting of 2020 on June 29, 2020, where several resolutions regarding the issuance of convertible bonds were approved[95]. - The annual general meeting on April 17, 2020, approved the 2019 annual report and financial statements, including profit distribution proposals[97]. - The company proposed no profit distribution or capital reserve transfer for the half-year period, with no bonus shares or cash dividends declared[98]. - The company confirmed compliance with commitments made by major shareholders and management regarding share transfer restrictions and future plans[99]. - The company reappointed Zhonghui Certified Public Accountants as its auditor for the 2020 financial year during the annual general meeting[102]. Environmental and Compliance - The company does not belong to the key pollutant discharge units and maintains non-severe pollution processes while managing suppliers to comply with environmental production requirements[113]. - The company has not disclosed any significant changes in accounting policies or estimates compared to the previous accounting period[114]. Investment and Capital Structure - The company plans to publicly issue 600 million RMB of convertible bonds to increase production capacity, with a projected design capacity of approximately 720,000 massage chairs upon completion of new projects[62]. - The company repurchased a total of 3,630,263 shares, accounting for 2.59% of the total share capital, with a total payment of approximately RMB 100.61 million[116]. - The total amount allocated for the share repurchase was between RMB 100 million and RMB 200 million[115]. - The company plans to publicly issue convertible bonds, pending approval from the China Securities Regulatory Commission, which carries uncertainty[119].

2020 年第一季度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2020 年第一季度报告 1 / 28 3 / 28 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 11 | 2020 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 1.2 公司全体董事出席董事会审议季度报告。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 2,316,011,598.50 2,461,373,036.61 -5.91 归属于上市公 司股东的净资 产 1,658,622,459.10 1,628,991,717.25 1.82 年初至报告期末 上年初至上年报告期 末 比上年同期增减(%) 经营活动产生 的现金流量净 额 -227,682,868.54 140,117, ...

Financial Performance - The company's operating revenue for 2019 was RMB 2,313,911,804.43, representing a year-on-year increase of 0.80% compared to RMB 2,295,648,224.52 in 2018[21] - The net profit attributable to shareholders of the listed company reached RMB 295,589,240.20, an increase of 18.61% from RMB 249,210,278.88 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 246,939,675.87, a decrease of 3.97% compared to RMB 257,148,110.94 in 2018[21] - The cash flow generated from operating activities was RMB 446,466,294.73, showing a significant increase of 70.83% from RMB 261,352,954.72 in the previous year[21] - The total assets of the company at the end of 2019 were RMB 2,461,373,036.61, reflecting a year-on-year growth of 13.59% from RMB 2,166,814,091.46 in 2018[21] - The net assets attributable to shareholders of the listed company increased to RMB 1,628,991,717.25, up 9.35% from RMB 1,489,679,528.56 at the end of 2018[21] - Basic earnings per share increased by 19.66% to CNY 2.13 in 2019 compared to CNY 1.78 in 2018[22] - The weighted average return on equity rose to 18.90% in 2019, an increase of 1.30 percentage points from 17.60% in 2018[22] - The total profit amounted to ¥327,788,425.25, reflecting a year-on-year increase of 16.29%[66] - The net profit attributable to the parent company was ¥295,589,240.20, up 18.61% compared to the previous year[66] Dividend Policy - The company plans to distribute a cash dividend of RMB 15.00 per 10 shares, totaling RMB 204,554,605.50 to all shareholders[5] - The company proposed a cash dividend of RMB 15.00 per 10 shares for the fiscal year ending December 31, 2019, which represents 69.20% of the net profit attributable to ordinary shareholders[126] - In 2018, the company distributed cash dividends totaling RMB 83,977,140.00, which was 33.70% of the net profit attributable to ordinary shareholders[125] - The company has consistently adhered to its cash dividend policy, ensuring stable returns for shareholders while expanding operational scale[123] Operational Efficiency - The company has maintained a standard unqualified audit opinion from its accounting firm, ensuring the accuracy and completeness of its financial reports[4] - The company aims to enhance its internal organizational structure to improve operational efficiency and management effectiveness[65] - The company has seen a notable increase in sales of massage chairs, with foreign sales growth significantly outpacing domestic sales, reflecting a robust global demand for massage products[57] - The company has successfully entered the overseas market, establishing stable partnerships and expanding its customer base in regions such as the US, EU, and Southeast Asia, leveraging its advantages in design, production management, and cost control[52] Market Strategy - The company employs a multi-channel sales model, including direct sales, e-commerce, and ODM for both domestic and international markets[35] - The company is actively exploring new marketing strategies, including leveraging live streaming and short video platforms to enhance domestic sales and brand visibility[59] - The company operates under a brand differentiation strategy with multiple brands, including "Rongtai" and "Momo Da," targeting different consumer segments and effectively mitigating market risks while enhancing brand recognition[49] - The company plans to expand production capacity through new production lines and factory construction, anticipating sustained high growth in the domestic massage chair market[64] Research and Development - The company is focusing on enhancing product technology through R&D investments, aiming to develop safer and more user-friendly massage products[45] - The company has made significant progress in R&D, with new massage chair models incorporating advanced technologies set to be launched in 2019[61] - Research and development expenses amounted to approximately ¥122.60 million, which is 5.30% of total revenue, reflecting a 12.73% increase from the previous year[78] Risk Management - The company emphasizes the importance of risk awareness regarding future plans and potential risks[6] - The company faces risks related to raw material price fluctuations, which constitute over 80% of its cost structure, potentially impacting profit growth[116] - The uncertainty in international trade, particularly regarding US-China negotiations, may negatively affect the company's performance, necessitating a focus on enhancing product competitiveness[121] Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, ensuring clear responsibilities and checks and balances[198] - The company has set up four specialized committees: Strategic Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with established working rules for each[199] - The governance practices comply with the regulatory requirements of the China Securities Regulatory Commission, with no significant discrepancies noted[199] Social Responsibility - The company has a volunteer team of 150 members, accounting for 20% of total employees, with 40% of volunteers being party members[164] - The company donated 300,000 RMB to the Tongji University Education Development Foundation and 20,000 RMB to the charity fund in Huzhou[165] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,730, an increase from 8,534 at the end of the previous month[170] - The largest shareholder, Lin Qi, holds 40,500,400 shares, representing 28.93% of the total shares[171] - The company has no controlling shareholder, with Lin Guangrong and Lin Qi being the natural persons in control[176] Employee Information - The total number of employees in the parent company and major subsidiaries is 1,501, with 791 in the parent company and 710 in subsidiaries[192] - The company has 970 production personnel, 186 sales personnel, 170 technical personnel, 42 financial personnel, and 133 administrative personnel[192] - The total hours of outsourced labor amounted to 187.43 thousand hours, with total payments for outsourced labor reaching CNY 61.7188 million[196]

2019 年第三季度报告 1 / 23 2019 年第三季度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2019 年第三季度报告 2 / 23 | 目录 | | --- | | 一、 | 重要提示 | 4 | | --- | --- | --- | | 二、 | 公司基本情况 | 4 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 8 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人林琪、主管会计工作负责人应建森及会计机构负责人（会计主管人员）廖金花保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比 上年度末增减 | | | --- | --- | --- | --- | --- | | | ...

2019 年半年度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2019 年半年度报告 1 / 198 2019 年半年度报告 重要提示 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意 投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 详细情况见本半年度报告第四节"经营情况讨论与分析"—"其他披露事项"—"可能面对 的风险"。 十、 其他 □适用 √不适用 2 / 198 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人林琪、主管会计工作负责人应建森及会计机构负责人（会计主管人员）廖金花声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 | ...

2018 年年度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2018 年年度报告（修订） 1 / 262 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 三、 中汇会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人林琪、主管会计工作负责人应建森及会计机构负责人（会计主管人员） 廖金花声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经公司第二届董事会第十九次会议审议通过公司2018年度分配利润预案为：以公 司2018年度利润分配方案实施时股权登记日的总股本为基数，向全体股东每 10 股派 发现金股利人民币3.00元（含税），不进行资本公积转增股本。剩余未分配利润结转 以后年度。 此议案尚需经公司股东大会批准后实施。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及未来计划等前瞻性陈述，不构成 ...

2019 年第一季度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2019 年第一季度报告 1 / 22 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 10 | 2019 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 3 / 22 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 2,227,865,972.33 2,166,814,091.46 2.82 归属于上市公 司股东的净资 产 1,547,410,608.58 1,489,679,528.56 3.88 年初至报告期末 上年初至上年报告期 末 比上年同期增减(%) 经营活动产生 的现金流量净 额 140,117,835.39 55,937,908.85 150.49 年初至报告期末 上年初至上年报告期 末 比上年同期增减（%） 营业收入 511,128,118.88 602,891,432.15 -15.22 归属于上市公 司股东的净利 润 57,7 ...

2018 年年度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2018 年年度报告 1 / 281 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 三、 中汇会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人林琪、主管会计工作负责人应建森及会计机构负责人（会计主管人员） 廖金花声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经公司第二届董事会第十九次会议审议通过公司2018年度分配利润预案为：以公 司2018年度利润分配方案实施时股权登记日的总股本为基数，向 ...

2018 年第三季度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2018 年第三季度报告 1 / 24 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人林琪、主管会计工作负责人应建森及会计机构负责人（会计主管人员）贾晓丽保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | --- | | | | | | 减(%) | | ...

2018 年半年度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2018 年半年度报告 1 / 155 2018 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人林琪、主管会计工作负责人应建森及会计机构负责人（会计主管人员）贾晓丽声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2018年8月1日公司第二届董事会第十五次会议审议通过公司2018年半年度利润分配预案为： 向全体股东按每10股3.00元实行利润分配，分配金额为 42,000,000.00 元，本次分配不送红股， 不进行资本公积金转增股本。该议案尚需经公司股东大会批准后实施。 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意 投资风险。 七、 是否存在被控股股东 ...